Page last updated: 2024-11-04

uroporphyrinogen iii

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Uroporphyrinogens: Porphyrinogens which are intermediates in heme biosynthesis. They have four acetic acid and four propionic acid side chains attached to the pyrrole rings. Uroporphyrinogen I and III are formed from polypyrryl methane in the presence of uroporphyrinogen III cosynthetase and uroporphyrin I synthetase, respectively. They can yield uroporphyrins by autooxidation or coproporphyrinogens by decarboxylation. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID1179
CHEBI ID15437
SCHEMBL ID80064
MeSH IDM0022408

Synonyms (29)

Synonym
up3 ,
uroporphyrinogen iii (6ci,7ci)
2,7,12,18-porphinetetrapropionic acid, 3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydro-
21h,23h-porphine-2,7,12,18-tetrapropanoic acid, 3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydro- (9ci)
2,7,12,18-porphinetetrapropionic acid, 3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydro- (8ci)
21h,23h-porphine-2,7,12,18-tetrapropanoic acid, 3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydro-
urogen iii
uro'gen iii
3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydro-21h,23h-porphine-2,7,12,18-tetrapropanoic acid
CHEBI:15437
3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydroporphyrin-2,7,12,18-tetrapropionic acid
3,3',3'',3'''-[3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydroporphyrin-2,7,12,18-tetrayl]tetrapropanoic acid
C01051
UROPORPHYRINOGEN-III ,
1976-85-8
uroporphyrinogen iii
uroporphyrinogens
3-[7,12,18-tris(2-carboxyethyl)-3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,21,22,23,24-octahydroporphyrin-2-yl]propanoic acid
UP2 ,
SCHEMBL80064
DTXSID40173444
3-[9,14,20-tris(2-carboxyethyl)-5,10,15,19-tetrakis(carboxymethyl)-21,22,23,24-tetraazapentacyclo[16.2.1.1^{3,6}.1^{8,11}.1^{13,16}]tetracosa-1(20),3,5,8,10,13,15,18-octaen-4-yl]propanoic acid
uroporphyrinogen
3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydro-2,7,12,18-porphinetetrapropionic acid
3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydro-2,7,12,18-porphinetetrapropionate
3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydro-21h,23h-porphine-2,7,12,18-tetrapropanoate
3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydroporphyrin-2,7,12,18-tetrapropanoic acid
3,8,13,17-tetrakis(carboxymethyl)-5,10,15,20,22,24-hexahydroporphyrin-2,7,12,18-tetrapropanoate
Q897727

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" An antibody raised against CYP2B1 markedly inhibited the PCB-dependent bilirubin degradation and PROD activities of phenobarbital-induced microsomes with similar dose-response curves for the two effects."( Bilirubin and uroporphyrinogen oxidation by induced cytochrome P4501A and cytochrome P4502B. Role of polyhalogenated biphenyls of different configuration.
Dawson, SJ; De Matteis, F; Pipino, S; Pons, N, 2002
)
0.31
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
uroporphyrinogen
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (14)

PathwayProteinsCompounds
Metabolism14961108
Porphyrin metabolism2344
Heme biosynthesis1530
Porphyrin Metabolism1636
Acute Intermittent Porphyria1636
Porphyria Variegata (PV)1636
Congenital Erythropoietic Porphyria (CEP) or Gunther Disease1636
Hereditary Coproporphyria (HCP)1636
Porphyrin_metabolism ( Porphyrin metabolism )716
HMOX1 pathway (COVID-19 Disease Map)3630
Hemesynthesis defects and porphyrias018
heme biosynthesis from uroporphyrinogen-III II012
Biochemical pathways: part I0466
Tetrapyrrole biosynthesis I514
Heme synthesis324

Research

Studies (174)

TimeframeStudies, This Drug (%)All Drugs %
pre-199069 (39.66)18.7374
1990's56 (32.18)18.2507
2000's31 (17.82)29.6817
2010's14 (8.05)24.3611
2020's4 (2.30)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 33.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index33.51 (24.57)
Research Supply Index5.18 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index41.24 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (33.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews10 (5.65%)6.00%
Case Studies6 (3.39%)4.05%
Observational0 (0.00%)0.25%
Other161 (90.96%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]